Cyclacel Pharmaceuticals (NASDAQ:BGMS) Announces Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:BGMS) issued its quarterly earnings data on Monday. The company reported ($2.21) earnings per share for the quarter, Zacks reports. The business had revenue of $0.67 million for the quarter.

Cyclacel Pharmaceuticals Trading Up 3.8%

Shares of BGMS opened at $1.00 on Wednesday. The firm has a market cap of $4.90 million, a PE ratio of -0.01 and a beta of -0.45. Cyclacel Pharmaceuticals has a 12-month low of $0.73 and a 12-month high of $100.75. The stock has a 50-day moving average price of $1.03.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cyclacel Pharmaceuticals in a research report on Friday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cyclacel Pharmaceuticals presently has an average rating of “Sell”.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.